Tools and Tweaks to Improve Sleep Quality in Patients With Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Jun Mao describes practical changes that have boosted sleep quality in cancer patients, and highlights results of a study showing sleep benefits from both CBT and acupuncture. 

In this video, Dr. Jun Mao describes practical changes that have boosted sleep quality in cancer patients, and highlights results of a study showing sleep benefits from both CBT and acupuncture.

 

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Related Content
A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer

Roman Fabbricatore
October 19th 2025
Article

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC

Russ Conroy
October 19th 2025
Article

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.

Capivasertib Combo Improves rPFS in PTEN-Deficient HSPC Population

Silas Inman
October 19th 2025
Article

Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

I-DXd Yields Promising Intracranial Efficacy in ES-SCLC Population

Kristi Rosa
October 19th 2025
Article

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.